<p>According to a survey-based study published by <a href="https://www.wiley.com/" target=" blank">Wiley</a> online in <em><a href="https://acsjournals.onlinelibrary.wiley.com/journal/10970142?dmmsmid=73865&dmmspid=22624228&dmmsuid=1961220" target=" blank">CANCER</a></em>, lesbian, gay, and bisexual (LGB) adolescents and young adult cancer survivors in the United States are more likely to report experiencing chronic health conditions than their heterosexual peers with a history of cancer as well as their LGB peers without a past cancer diagnosis.</p>
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.
Investigators from Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center and leading cancer program along with Tufts Medical Center in Boston, developed and validated the Advanced-stage Hodgkin lymphoma International Prognostication Index (A-HIPI).